M3 KK header image

M3 KK

2413

Equity

ISIN JP3435750009 / Valor 1929657

Tokyo Stock Exchange (2024-09-12)
JPY 1,349.50+3.17%

M3 KK
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

M3 KK, a prominent entity in the healthcare sector, has distinguished itself by being the first company incorporated after the year 2000 to join the prestigious Nikkei 225 Index. With a substantial network comprising over 330,000 Japanese and more than 6.5 million global physician members, M3 operates at the forefront of healthcare innovation and reform on a worldwide scale. The company leverages this extensive panel of medical professionals to facilitate advancements in healthcare practices, technologies, and services. While the source does not delve into specific products or services, M3's significant engagement with such a large community of healthcare providers underscores its pivotal role in shaping future healthcare landscapes through collaboration, research, and the dissemination of medical knowledge across global boundaries.

Summarized from source with an LLMView SourceSector: Technology

Latest Results (14.08.2024):

Revenue Growth

M3 KK reported a revenue of 64,209 million yen for the three months ended June 30, 2024, marking an 11.9% increase compared to the same period in 2023. This growth reflects the company's successful expansion and increased demand for its services.

Operating Profit Decline

Despite the revenue growth, M3 KK's operating profit for Q1 2024 decreased by 6.1% year-on-year, amounting to 16,899 million yen. This decline indicates higher operational costs or investments that impacted the profitability for the quarter.

Profit Before Tax

For the first quarter of 2024, M3 KK's profit before tax was 18,784 million yen, a 5.3% decrease from the previous year's 19,831 million yen. This reduction suggests challenges in maintaining pre-tax profitability despite increased revenues.

Net Profit

M3 KK's net profit attributable to owners of the parent for the three months ended June 30, 2024, was 12,750 million yen, down 5.9% from 13,554 million yen in the same period of 2023. This decline in net profit highlights the impact of increased expenses or other financial factors on the bottom line.

Dividends

M3 KK has announced that the dividend forecast for the fiscal year ending March 31, 2025, is currently undetermined. The company plans to decide on the dividend payments after considering capital needs and cash flow conditions in the future.

Summarized from source with an LLMView Source

Key figures

-51.8%1Y
-83.5%3Y
-43.7%5Y

Performance

40.9%1Y
41.6%3Y
41.3%5Y

Volatility

Market cap

6505 M

Market cap (USD)

Daily traded volume (Shares)

3,704,000

Daily traded volume (Shares)

1 day high/low

1373 / 1318

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

F5 Inc
F5 Inc F5 Inc Valor: 812258
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.12%USD 210.31
Affirm Holdings Inc
Affirm Holdings Inc Affirm Holdings Inc Valor: 58463675
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.44%USD 44.01
AppFolio Inc
AppFolio Inc AppFolio Inc Valor: 28315793
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.72%USD 225.84
Kymera Therapeutics Inc
Kymera Therapeutics Inc Kymera Therapeutics Inc Valor: 56388008
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.04%USD 46.08
Agilysys Inc
Agilysys Inc Agilysys Inc Valor: 1680840
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.06%USD 102.17
Perficient Inc
Perficient Inc Perficient Inc Valor: 854280
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.08%USD 75.50
Cartesian Therapeutics Inc
Cartesian Therapeutics Inc Cartesian Therapeutics Inc Valor: 134256445
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.23%USD 16.75
Agios Pharmaceuticals Inc
Agios Pharmaceuticals Inc Agios Pharmaceuticals Inc Valor: 21630028
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.94%USD 46.69
Vertex Inc
Vertex Inc Vertex Inc Valor: 55908112
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.77%USD 36.24
SoftBank Group KK
SoftBank Group KK SoftBank Group KK Valor: 245595
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
7.95%JPY 8,500.00